128 related articles for article (PubMed ID: 35977805)
1. Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures.
Wright D; Britten J; Malik M; Catherino WH
F S Sci; 2022 Aug; 3(3):299-308. PubMed ID: 35977805
[TBL] [Abstract][Full Text] [Related]
2. Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.
Cox J; Malik M; Britten J; Lewis T; Catherino WH
Reprod Sci; 2018 Feb; 25(2):198-206. PubMed ID: 28929861
[TBL] [Abstract][Full Text] [Related]
3. Hop and artichoke extracts inhibit expression of extracellular matrix components in uterine leiomyoma cells.
Islam MS; Greco S; Delli Carpini G; Giannubilo SR; Segars J; Ciavattini A; Ciarmela P
F S Sci; 2021 Nov; 2(4):407-418. PubMed ID: 35559863
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
Malik M; Britten J; Cox J; Patel A; Catherino WH
Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
6. A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy.
Sasamori Y; Takehara K; Terashima T; Onodera T; Yatsuki K; Nakagawa I; Takahashi Y; Nishida H; Ichinose T; Hiraike H; Nagasaka K
BMC Womens Health; 2021 Aug; 21(1):306. PubMed ID: 34412607
[TBL] [Abstract][Full Text] [Related]
7. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
[TBL] [Abstract][Full Text] [Related]
8. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
9. Mifepristone inhibits extracellular matrix formation in uterine leiomyoma.
Patel A; Malik M; Britten J; Cox J; Catherino WH
Fertil Steril; 2016 Apr; 105(4):1102-10. PubMed ID: 26776909
[TBL] [Abstract][Full Text] [Related]
10. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
11. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
Hoshiai H; Seki Y; Kusumoto T; Kudou K; Tanimoto M
BMC Womens Health; 2021 Oct; 21(1):375. PubMed ID: 34711224
[TBL] [Abstract][Full Text] [Related]
12. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
13. Liarozole inhibits transforming growth factor-β3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures.
Levy G; Malik M; Britten J; Gilden M; Segars J; Catherino WH
Fertil Steril; 2014 Jul; 102(1):272-281.e2. PubMed ID: 24825427
[TBL] [Abstract][Full Text] [Related]
14. Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent.
Gilden M; Malik M; Britten J; Delgado T; Levy G; Catherino WH
Fertil Steril; 2012 Dec; 98(6):1557-62. PubMed ID: 22925684
[TBL] [Abstract][Full Text] [Related]
15. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Osuga Y; Enya K; Kudou K; Hoshiai H
Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
[TBL] [Abstract][Full Text] [Related]
16. Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.
Janjusevic M; Greco S; Islam MS; Castellucci C; Ciavattini A; Toti P; Petraglia F; Ciarmela P
Fertil Steril; 2016 Nov; 106(6):1530-1538.e1. PubMed ID: 27565262
[TBL] [Abstract][Full Text] [Related]
17. Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection.
Takeda A
J Obstet Gynaecol Res; 2022 Jul; 48(7):1921-1929. PubMed ID: 35460303
[TBL] [Abstract][Full Text] [Related]
18. Relugolix for the treatment of uterine fibroids.
Barra F; Seca M; Della Corte L; Giampaolino P; Ferrero S
Drugs Today (Barc); 2019 Aug; 55(8):503-512. PubMed ID: 31461087
[TBL] [Abstract][Full Text] [Related]
19. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
20. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
